HRP20120073T1 - NOVI KRISTALNI OBLIK DERIVATA PIRIDAZINO[ b]INDOLA - Google Patents
NOVI KRISTALNI OBLIK DERIVATA PIRIDAZINO[ b]INDOLA Download PDFInfo
- Publication number
- HRP20120073T1 HRP20120073T1 HRP20120073TT HRP20120073T HRP20120073T1 HR P20120073 T1 HRP20120073 T1 HR P20120073T1 HR P20120073T T HRP20120073T T HR P20120073TT HR P20120073 T HRP20120073 T HR P20120073T HR P20120073 T1 HRP20120073 T1 HR P20120073T1
- Authority
- HR
- Croatia
- Prior art keywords
- prevention
- treatment
- intended
- crystalline form
- pharmaceutical preparation
- Prior art date
Links
- LDBZRFQWKQUHFF-UHFFFAOYSA-N 5h-pyridazino[4,5-b]indole Chemical class N1=NC=C2C3=CC=CC=C3NC2=C1 LDBZRFQWKQUHFF-UHFFFAOYSA-N 0.000 title 1
- 238000002441 X-ray diffraction Methods 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract 2
- 230000005855 radiation Effects 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000019622 heart disease Diseases 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- HJSQVJOROCIILI-UHFFFAOYSA-N ssr-180,575 Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(CC(=O)N(C)C)=NN1C1=CC=CC=C1 HJSQVJOROCIILI-UHFFFAOYSA-N 0.000 claims 3
- 102000004300 GABA-A Receptors Human genes 0.000 claims 2
- 108090000839 GABA-A Receptors Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 239000011261 inert gas Substances 0.000 claims 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Kristalni oblik spoja Formule A označen kao Oblik II naznačen time što mu uzorak difrakcije rendgenskih zraka sadrži pikove na ± ° ° i ° gdje su uzorci XRPDdobiveni difraktometrom rendgenskih zraka na prahu uz pomoć zračenja K a uzorci su skenirani brzinom od ° u minuti od do ° pod uglom od Patent sadrži još patentnih zahtjeva
Claims (21)
1. Kristalni oblik spoja Formule (A):
[image]
označen kao Oblik II, naznačen time što mu uzorak difrakcije rendgenskih zraka sadrži pikove na (± 0,15° 2θ): 5.71°, 11,47 i 9,97° 2θ, gdje su uzorci XRPD dobiveni difraktometrom rendgenskih zraka na prahu, uz pomoć zračenja Kα, a uzorci su skenirani brzinom od 1,0° u minuti, od 2 do 40°, pod uglom od 2θ.
2. Kristalni oblik u skladu s patentnim zahtjevom 1, naznačen time što uzorak difrakcije rendgenskih zraka također sadrži pikove na (± 0,15° 2θ): 19,21, 18,43, 15,95, te 11,97° 2θ.
3. Kristalni oblik u skladu s patentnim zahtjevom 1, naznačen time što je uglavnom čist od bilo kojeg drugog polimorfa.
4. Farmaceutski pripravak, naznačen time što sadrži kristalni oblik u skladu s patentnim zahtjevom 1 i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
5. Kristalni oblik u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen liječenju ili sprječavanju bolesti ili poremećaja povezanog s disfunkcijom perifernog tipa benzodiazepinskih receptora.
6. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što je namijenjen liječenju ili sprječavanju bolesti ili poremećaja povezanog s disfunkcijom perifernog tipa benzodiazepinskih receptora.
7. Kristalni oblik u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen liječenju ili sprječavanju neurodegenerativne bolesti.
8. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što je namijenjen liječenju ili sprječavanju neurodegenerativne bolesti.
9. Kristalni oblik u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen liječenju ili sprječavanju neuropatije.
10. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što je namijenjen liječenju ili sprječavanju neuropatije.
11. Kristalni oblik u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen liječenju ili sprječavanju raka ili tumora.
12. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što je namijenjen liječenju ili sprječavanju raka ili tumora.
13. Kristalni oblik u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen liječenju ili sprječavanju kutanog stresa.
14. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što je namijenjen liječenju ili sprječavanju kutanog stresa.
15. Kristalni oblik u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen liječenju ili sprječavanju reumatoidnog artritisa.
16. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što je namijenjen liječenju ili sprječavanju reumatoidnog artritisa.
17. Kristalni oblik u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen liječenju ili sprječavanju bolesti srca ili poremećaja srca.
18. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što je namijenjen liječenju ili sprječavanju bolesti srca ili poremećaja srca.
19. Postupak dobivanja kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u koracima miješanja 7-klor-N,N,5-trimetil-4-okso-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida s nižim alkoholom, primjerice metanolom ili etanolom, u koncentraciji od otprilike 1 mg/ml do otprilike 4 mg/ml, kako bi se dobilo smjesu, grijanja smjese do temperature između otprilike 45 °C i otprilike 60 °C, filtriranja smjese, te otparavanja nižeg alkohola iz filtrata strujom inertnog plina kako bi se dobilo krutinu.
20. Postupak dobivanja kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u koracima otapanja 7-klor-N,N,5-trimetil-4-okso-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida u diklormetanu, u koncentraciji od otprilike 30 mg/ml do otprilike 50 mg/ml, kako bi se dobilo otopinu; dodavanja otopine u etanol, u omjeru od otprilike 1:3 do otprilike 1:4, volumno, u odnosu na količinu diklormetana, zatim koncentriranja otopine, smanjivanja volumena za otprilike 10% do otprilike 40% strujom inertnog plina dok se krutina ne iskristalizira, te izdvajanja krutine.
21. Postupak dobivanja kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u koracima otapanja 7-klor-N,N,5-trimetil-4-okso-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida u diklormetanu, u koncentraciji od otprilike 20 mg/ml do otprilike 50 mg/ml, kako bi se dobilo otopinu, dodavanja otopine u heksane kako bi došlo do taloženja krutine, te izdvajanja krutine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71215305P | 2005-08-29 | 2005-08-29 | |
| PCT/US2006/033254 WO2007027525A1 (en) | 2005-08-29 | 2006-08-24 | Novel crystalline form of a pyridazino [4 , 5-b] indole derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120073T1 true HRP20120073T1 (hr) | 2012-07-31 |
Family
ID=37546937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120073TT HRP20120073T1 (hr) | 2005-08-29 | 2012-01-23 | NOVI KRISTALNI OBLIK DERIVATA PIRIDAZINO[ b]INDOLA |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US7683062B2 (hr) |
| EP (1) | EP1924585B1 (hr) |
| JP (1) | JP5063600B2 (hr) |
| KR (2) | KR20080050577A (hr) |
| CN (1) | CN101253176B (hr) |
| AR (1) | AR057099A1 (hr) |
| AT (1) | ATE531717T1 (hr) |
| AU (1) | AU2006285142B2 (hr) |
| BR (1) | BRPI0615259A2 (hr) |
| CA (1) | CA2619284C (hr) |
| CR (1) | CR9723A (hr) |
| CY (1) | CY1112317T1 (hr) |
| DK (1) | DK1924585T3 (hr) |
| EA (1) | EA014164B1 (hr) |
| EC (1) | ECSP088209A (hr) |
| ES (1) | ES2375841T3 (hr) |
| HK (1) | HK1123794A1 (hr) |
| HR (1) | HRP20120073T1 (hr) |
| IL (1) | IL189276A (hr) |
| MA (1) | MA30000B1 (hr) |
| NO (1) | NO20081365L (hr) |
| NZ (1) | NZ566087A (hr) |
| PL (1) | PL1924585T3 (hr) |
| PT (1) | PT1924585E (hr) |
| RS (1) | RS52318B (hr) |
| SI (1) | SI1924585T1 (hr) |
| TN (1) | TNSN08059A1 (hr) |
| TW (1) | TW200813060A (hr) |
| UA (1) | UA91716C2 (hr) |
| UY (1) | UY29771A1 (hr) |
| WO (1) | WO2007027525A1 (hr) |
| ZA (1) | ZA200801890B (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007536210A (ja) * | 2003-11-17 | 2007-12-13 | メルック・エプロバ・アクチエンゲゼルシヤフト | （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形 |
| JP2008501657A (ja) * | 2004-06-02 | 2008-01-24 | サンド・アクチエンゲゼルシヤフト | 結晶形態のメロペネム中間体 |
| BRPI0616040A2 (pt) * | 2005-09-21 | 2011-06-07 | Nycomed Gmbh | cloridrato de sulfonilpirról como inibidor de histona desacetilases |
| EP1951700A2 (en) * | 2005-10-31 | 2008-08-06 | Janssen Pharmaceutica N.V. | Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives |
| EP2044020B1 (en) * | 2006-06-16 | 2011-05-04 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| MX2009003913A (es) * | 2006-10-27 | 2009-04-24 | Signal Pharm Llc | Formas solidas que comprenden 4-[9-(tetrahidro-furano-3-il)-8-(2,4 ,6-trifluoro-fenilamino)-9h-purin-2-ilamino]-ciclohexan-1-ol, composiciones de las mismas, y su uso. |
| EP2085397A1 (en) * | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
| US7935817B2 (en) * | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
| AR071318A1 (es) * | 2008-04-15 | 2010-06-09 | Basilea Pharmaceutica Ag | Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso |
| US8097719B2 (en) * | 2008-07-15 | 2012-01-17 | Genesen Labs | Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem |
| KR20110052640A (ko) * | 2008-08-18 | 2011-05-18 | 사노피-아벤티스 유.에스. 엘엘씨 | 7-클로로-Ｎ,Ｎ,5-트리메틸-4-옥소-3-페닐-3,5-디하이드로-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드의 다형체의 제조방법 |
| NZ601967A (en) | 2010-03-12 | 2015-03-27 | Omeros Corp | Pde10 inhibitors and related compositions and methods |
| EP2611433A2 (en) * | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
| WO2013044816A1 (en) * | 2011-09-30 | 2013-04-04 | Sunshine Lake Pharma Co., Ltd. | Crystalline forms of azilsartan and preparation and uses thereof |
| NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| EP3285760A4 (en) | 2015-04-24 | 2018-09-26 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| JP2018535969A (ja) | 2015-11-04 | 2018-12-06 | オメロス コーポレーション | Ｐｄｅ１０阻害剤の固体状態形態 |
| CN111303230B (zh) * | 2020-03-09 | 2021-07-13 | 中国食品药品检定研究院 | 一种黄体酮共晶物及其制备方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766823B1 (fr) * | 1997-07-30 | 1999-10-08 | Synthelabo | Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique |
| FR2788696B1 (fr) * | 1999-01-26 | 2004-03-05 | Synthelabo | Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central |
| FR2829939B3 (fr) | 2001-09-21 | 2003-11-28 | Sanofi Synthelabo | Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide |
| WO2005034999A2 (en) | 2003-10-10 | 2005-04-21 | Bvm Holding Co. | Composition comprising association complex of a pharmaceutical and a poloxamer |
-
2006
- 2006-08-24 UA UAA200803953A patent/UA91716C2/ru unknown
- 2006-08-24 ES ES06813757T patent/ES2375841T3/es active Active
- 2006-08-24 SI SI200631252T patent/SI1924585T1/sl unknown
- 2006-08-24 CA CA2619284A patent/CA2619284C/en not_active Expired - Fee Related
- 2006-08-24 NZ NZ566087A patent/NZ566087A/en not_active IP Right Cessation
- 2006-08-24 EA EA200800716A patent/EA014164B1/ru not_active IP Right Cessation
- 2006-08-24 KR KR1020087004953A patent/KR20080050577A/ko active IP Right Grant
- 2006-08-24 DK DK06813757.9T patent/DK1924585T3/da active
- 2006-08-24 JP JP2008529130A patent/JP5063600B2/ja not_active Expired - Fee Related
- 2006-08-24 AU AU2006285142A patent/AU2006285142B2/en not_active Ceased
- 2006-08-24 PT PT06813757T patent/PT1924585E/pt unknown
- 2006-08-24 KR KR1020137018636A patent/KR20130087059A/ko not_active Application Discontinuation
- 2006-08-24 PL PL06813757T patent/PL1924585T3/pl unknown
- 2006-08-24 EP EP06813757A patent/EP1924585B1/en active Active
- 2006-08-24 AT AT06813757T patent/ATE531717T1/de active
- 2006-08-24 BR BRPI0615259-7A patent/BRPI0615259A2/pt not_active IP Right Cessation
- 2006-08-24 RS RS20120032A patent/RS52318B/en unknown
- 2006-08-24 WO PCT/US2006/033254 patent/WO2007027525A1/en active Application Filing
- 2006-08-24 ZA ZA200801890A patent/ZA200801890B/xx unknown
- 2006-08-24 CN CN2006800314750A patent/CN101253176B/zh not_active Expired - Fee Related
- 2006-08-28 AR ARP060103740A patent/AR057099A1/es not_active Application Discontinuation
- 2006-08-29 TW TW095131681A patent/TW200813060A/zh unknown
- 2006-08-29 UY UY29771A patent/UY29771A1/es unknown
-
2008
- 2008-02-04 IL IL189276A patent/IL189276A/en not_active IP Right Cessation
- 2008-02-06 TN TNP2008000059A patent/TNSN08059A1/en unknown
- 2008-02-11 CR CR9723A patent/CR9723A/es unknown
- 2008-02-14 US US12/031,243 patent/US7683062B2/en not_active Expired - Fee Related
- 2008-02-20 EC EC2008008209A patent/ECSP088209A/es unknown
- 2008-03-14 NO NO20081365A patent/NO20081365L/no not_active Application Discontinuation
- 2008-03-17 MA MA30757A patent/MA30000B1/fr unknown
-
2009
- 2009-02-19 HK HK09101601.0A patent/HK1123794A1/xx not_active IP Right Cessation
-
2012
- 2012-01-23 HR HRP20120073TT patent/HRP20120073T1/hr unknown
- 2012-01-26 CY CY20121100092T patent/CY1112317T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120073T1 (hr) | NOVI KRISTALNI OBLIK DERIVATA PIRIDAZINO[ b]INDOLA | |
| CN113354685B (zh) | 作为egfr激酶抑制剂的芳基磷氧化合物 | |
| US10017513B2 (en) | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | |
| CN111344290A (zh) | 作为Wee1抑制剂的大环类化合物及其应用 | |
| JPH08337584A (ja) | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 | |
| JP2022500476A (ja) | 環状ジヌクレオチド類似体、その医薬組成物及び使用 | |
| CN106232602B (zh) | 氘代喹唑啉酮化合物以及包含该化合物的药物组合物 | |
| CN114437077B (zh) | 用作激酶抑制剂的化合物及其应用 | |
| WO2016098070A1 (en) | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine | |
| AU2005318227B2 (en) | Stereoselective process and crystalline forms of a camptothecin | |
| CN111918859B (zh) | 稠合三环γ-氨基酸衍生物的盐的晶型及制备和应用 | |
| CN111303178B (zh) | Ovatodiolide衍生物及其盐，制备方法及其在制备抗癌药物中的用途 | |
| CN110049765B (zh) | 一种组合、其应用及治疗方法 | |
| CN114667288A (zh) | 苯并菲啶生物碱及其使用方法 | |
| CN112830930B (zh) | Eoc317的晶型及其制备方法与应用 | |
| TW202007690A (zh) | 氮雜環丁烷衍生物的硼酸酯 | |
| WO2023197934A1 (zh) | 阿片受体拮抗剂缀合物的固体盐型、晶型及其制备方法、组合物和用途 | |
| JP5701884B2 (ja) | 三環性ピラゾロピリミジン誘導体の結晶 | |
| CN116529249A (zh) | 吡啶并嘧啶酮类化合物 | |
| EP4159736A1 (en) | Novel tricyclic aromatic heterocyclic compound and preparation method therefor, pharmaceutical composition and use thereof | |
| CN117343064A (zh) | 一种具有抗病毒作用的嘧啶衍生物的制备与应用 | |
| CN117247382A (zh) | 吡啶并嘧啶酮化合物的晶型 | |
| CN114874217A (zh) | 苯并氮杂卓衍生物的盐、溶剂合物、多晶型物、制备方法及应用 | |
| EA040849B1 (ru) | Кислородсодержащее арилфосфорное соединение в качестве ингибитора киназы egfr | |
| WO2012026433A1 (ja) | 三環性ピラゾロピリミジン誘導体のフリー体結晶 |